Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 5Phase 3 2Phase 2/3 2Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Myeloid 1Head & Neck 1Gastrointestinal 1CNS 1

Conditions

Thyroid Neoplasms 1Lung Neoplasms 1Histiocytosis 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

pembrolizumab 83Cyclophosphamide 55Specimen Handling 54Carboplatin 53fludarabine 44Nivolumab 43Magnetic Resonance Spectroscopy 43Gemcitabine 41Biopsy 40venetoclax 33Bevacizumab 33Dexamethasone 31Paclitaxel 29Pemetrexed 27Injections 27Cisplatin 27Docetaxel 26Azacitidine 22atezolizumab 21Rituximab 21Oxaliplatin 21Capecitabine 21Lenalidomide 20Ipilimumab 20Temozolomide 19Fulvestrant 19Cetuximab 19abemaciclib 18Fluorouracil 18Cytarabine 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × IFL protocol × 90 days × Clear all
NCT05786924 2026-04-21

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Servier

Phase 1/2 Recruiting
554 enrolled
CNSGastrointestinalHead & NeckMyeloidThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡